Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDIT NASDAQ:LENZ NASDAQ:RZLT NASDAQ:SPRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$3.12+2.5%$2.63$1.29▼$4.54$304.30M2.141.68 million shs586,652 shsLENZLENZ Therapeutics$9.50+4.7%$10.60$8.25▼$50.40$291.71M0.62987,275 shs235,318 shsRZLTRezolute$3.21-2.6%$3.15$1.07▼$11.46$307.68M0.662.86 million shs320,308 shsSPRBSpruce Biosciences$58.48-1.5%$61.12$4.35▼$240.00$80.11M3.2653,851 shs15,800 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine+4.83%-0.65%+13.86%+55.90%+97.40%LENZLENZ Therapeutics+2.14%-2.37%-6.20%-37.96%-68.83%RZLTRezolute-0.30%+7.17%+5.45%+13.06%-20.15%SPRBSpruce Biosciences+3.60%+8.34%-15.83%-25.10%+1,000.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$3.12+2.5%$2.63$1.29▼$4.54$304.30M2.141.68 million shs586,652 shsLENZLENZ Therapeutics$9.50+4.7%$10.60$8.25▼$50.40$291.71M0.62987,275 shs235,318 shsRZLTRezolute$3.21-2.6%$3.15$1.07▼$11.46$307.68M0.662.86 million shs320,308 shsSPRBSpruce Biosciences$58.48-1.5%$61.12$4.35▼$240.00$80.11M3.2653,851 shs15,800 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine+4.83%-0.65%+13.86%+55.90%+97.40%LENZLENZ Therapeutics+2.14%-2.37%-6.20%-37.96%-68.83%RZLTRezolute-0.30%+7.17%+5.45%+13.06%-20.15%SPRBSpruce Biosciences+3.60%+8.34%-15.83%-25.10%+1,000.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.57Moderate Buy$5.4073.35% UpsideLENZLENZ Therapeutics 2.63Moderate Buy$44.00363.16% UpsideRZLTRezolute 2.45Hold$8.00149.61% UpsideSPRBSpruce Biosciences 2.50Moderate Buy$190.60225.95% UpsideCurrent Analyst Ratings BreakdownLatest SPRB, EDIT, RZLT, and LENZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026EDITEditas Medicine Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.50 ➝ $4.004/27/2026SPRBSpruce Biosciences Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$140.004/21/2026LENZLENZ Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026RZLTRezolute Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026LENZLENZ Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$56.00 ➝ $48.004/20/2026EDITEditas Medicine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/26/2026LENZLENZ Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $26.003/25/2026LENZLENZ Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$35.00 ➝ $29.003/25/2026RZLTRezolute WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$2.00 ➝ $5.003/10/2026LENZLENZ Therapeutics William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform3/10/2026EDITEditas Medicine JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$8.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$40.52M7.53N/AN/A$0.28 per share11.13LENZLENZ Therapeutics$19.09M15.60N/AN/A$9.09 per share1.05RZLTRezoluteN/AN/AN/AN/A$1.86 per shareN/ASPRBSpruce Biosciences$4.91M16.32N/AN/A$39.72 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$160.06M-$1.89N/AN/AN/A-395.02%-389.73%-55.28%5/11/2026 (Estimated)LENZLENZ Therapeutics-$82.13M-$2.81N/AN/AN/AN/A-37.47%-35.13%5/6/2026 (Estimated)RZLTRezolute-$74.41M-$0.93N/AN/AN/AN/A-64.81%-59.37%5/12/2026 (Estimated)SPRBSpruce Biosciences-$38.97M-$51.72N/AN/AN/AN/A-203.99%-127.96%N/ALatest SPRB, EDIT, RZLT, and LENZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q3 2026RZLTRezolute-$0.1686N/AN/AN/AN/AN/A5/11/2026Q1 2026EDITEditas Medicine-$0.30-$0.26+$0.04-$0.26$6.37 million$2.83 million5/6/2026Q1 2026LENZLENZ Therapeutics-$1.10N/AN/AN/A$1.76 millionN/A3/24/2026Q4 2025LENZLENZ Therapeutics-$0.91-$1.16-$0.25-$1.16$3.09 million$1.59 million3/12/2026Q4 2025SPRBSpruce Biosciences-$9.1575-$9.58-$0.4225-$9.58N/AN/A3/9/2026Q4 2025EDITEditas Medicine-$0.27-$0.06+$0.21-$0.06$8.77 million$24.74 million2/12/2026Q2 2026RZLTRezolute-$0.16-$0.22-$0.06-$0.22N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A3.543.54LENZLENZ TherapeuticsN/A14.2314.09RZLTRezoluteN/A14.1814.18SPRBSpruce BiosciencesN/A5.175.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%LENZLENZ Therapeutics54.32%RZLTRezolute82.97%SPRBSpruce Biosciences91.71%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine1.90%LENZLENZ Therapeutics6.90%RZLTRezolute14.78%SPRBSpruce Biosciences4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23097.91 million96.05 millionOptionableLENZLENZ Therapeutics11031.35 million29.19 millionN/ARZLTRezolute4095.70 million81.55 millionOptionableSPRBSpruce Biosciences201.37 million1.31 millionOptionableSPRB, EDIT, RZLT, and LENZ HeadlinesRecent News About These CompaniesSpruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President ...May 4 at 11:40 PM | bakersfield.comBSpruce Biosciences (SPRB) Expected to Announce Earnings on TuesdayMay 3 at 3:50 AM | americanbankingnews.comSpruce Biosciences (SPRB) Projected to Post Earnings on TuesdayApril 28, 2026 | marketbeat.comCraig-Hallum initiates coverage of Spruce Biosciences (SPRB) with buy recommendationApril 28, 2026 | msn.comCraig Hallum Initiates Coverage on Spruce Biosciences (NASDAQ:SPRB)April 27, 2026 | marketbeat.comWhy is Spruce Biosciences stock sinking Tuesday?April 21, 2026 | msn.comSpruce Biosciences prices $60M public offering at $50.00 per shareApril 21, 2026 | msn.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Recommendation of "Hold" from BrokeragesApril 21, 2026 | marketbeat.comSpruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsApril 20, 2026 | businesswire.comSpruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsApril 20, 2026 | finance.yahoo.comWall Street Analysts Believe Spruce Biosciences (SPRB) Could Rally 181.21%: Here's is How to TradeApril 3, 2026 | zacks.comDoes Spruce Biosciences (SPRB) Have the Potential to Rally 208.32% as Wall Street Analysts Expect?March 18, 2026 | zacks.comSpruce Biosciences (SPRB) Appoints Dale Hooks as CCO and Reports Narrowed $39M 2025 Net LossMarch 17, 2026 | insidermonkey.comSpruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial OfficerMarch 9, 2026 | pharmiweb.comPSpruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate UpdatesMarch 9, 2026 | businesswire.comSpruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval PathwayMarch 3, 2026 | insidermonkey.comSpruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval PathwayMarch 3, 2026 | msn.comSpruce Biosciences to Present at Upcoming Investor Conferences in MarchMarch 2, 2026 | businesswire.comSPRB stock drops after company pushes back application submission timeline for experimental Sanfilippo syndrome therapyFebruary 18, 2026 | msn.comSpruce Biosciences reports positive FDA meetings as it prepares TA-ERT filing for rare pediatric disorderFebruary 18, 2026 | msn.comSpruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 17, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026This AI Lender Has Big Upside Potential—And Big Risks By Peter Frank | April 19, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026NerdWallet’s Growth Story Looks Strong—But Can It Last?By Peter Frank | April 30, 2026CPI Card Group’s Quiet Cash Machine Faces a Digital Reality CheckBy Peter Frank | May 4, 2026SPRB, EDIT, RZLT, and LENZ Company DescriptionsEditas Medicine NASDAQ:EDIT$3.12 +0.08 (+2.47%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.LENZ Therapeutics NASDAQ:LENZ$9.50 +0.43 (+4.74%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Rezolute NASDAQ:RZLT$3.20 -0.09 (-2.58%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Spruce Biosciences NASDAQ:SPRB$58.48 -0.86 (-1.46%) As of 12:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
